Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis.

ABSTRACT:

Background and objectives

Interdialytic weight gain in patients on hemodialysis is associated with adverse cardiovascular outcomes and increased mortality. The degree of interdialytic weight gain is influenced by sodium intake. We evaluated the effects of tenapanor (AZD1722 and RDX5791), a minimally systemically available inhibitor of the sodium/hydrogen exchanger isoform 3, on interdialytic weight gain in patients with CKD stage 5D treated with hemodialysis.

Design, setting, participants, & measurements

This phase 2, randomized, double-blind study (NCT01764854; conducted January to September of 2013) enrolled adults on maintenance hemodialysis with interdialytic weight gain ≥3.0% of postdialysis weight and ≥2 kg. Patients were randomly assigned (1:1) to receive tenapanor or

SUBMITTER: Block GA 

PROVIDER: S-EPMC5012484 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature